Home / Transcripts / Nanosonics Limited (NAN) · August 27, 2024

Nanosonics Limited (NAN) Earnings Call Transcript

August 27, 2024

Australian Securities Exchange AU Health Care Health Care Equipment and Supplies earnings 52 min

Earnings Call Speaker Segments

Operator operator
#1

We appreciate your holding, and you're welcome to the Nanosonics Limited 2024 Full Year Results Call. <<operator_script>>. At this point I'd like to pass the conference to Mr. Michael Kavanagh, Managing Director and CEO. Please proceed.

Michael Kavanagh executive
#2

Thank you so much, and a very good morning to everyone, and thanks for being with us this morning. I know how busy all of you are at this time of year. Jason Burriss, our CFO, is here with me today, and you'll be hearing from him shortly as he walks you through the specifics of the financial results for the year. Before that, I think while the effect of the hospital capital budget restrictions on our capital sales in the first half is well understood. A central theme for the full year results, I think, is the turnaround in performance in the second half over the first half. We saw our second half revenue of $90.4 million, up 14% on the first half. The course then deduct part was driven by our total capital unit sales were actually up 24% in the second half over the first with capital revenue up 20%. While the hospital budget constraints, they remain, the requirements for infection prevention has not changed. Together with the underlying positive fundamentals for infection prevention and importantly, a growing pipeline, we're pretty confident that the return to a growth profile that you saw in the second half will continue into this current financial year, as indicated in our business outlook, where we're targeting revenue growth to be in the range of 8% to 12%.

Michael Kavanagh executive
#3

This expansion, I believe, is going to stem from continued growth in capital units as well as an increase in our recurring revenue, which carries high margins. I'll get into the specifics of our outlook in a little while. As we typically do, we've included plenty of granular detail, particularly within the investor presentation, which is available online. That said, a few key takeaways or insights are worth highlighting from all that detail. The first is really that trophon's growth opportunity stays substantial across every region. There are really two sides to this. To begin with, we've already succeeded in establishing trophon as the standard of care across several major markets. Even though the fundamentals of adoption differ by region depending on where each stands today with respect to guidelines, we do expect that global demand for automated high-level disinfection of ultrasound transducers will in fact increase. Against that backdrop, trophon clearly stands out as the most advanced and proven solution on the market for meeting this need. The second side of this growth opportunity lies in North America, our largest market. Trophon has hit a significant milestone by achieving 50% penetration of the estimated 60,000 unit TAM. We definitely have strategies in place for reaching the remaining 50%, and that will be achieved through continued penetration into the many relevant departments in each hospital that use ultrasound — of which there are many — as well as by tapping the private physician office market via a number of specialized channel partners we have established.

Michael Kavanagh executive
#4

The second thing I'd point out is that apart from what we're putting into the longer-term growth plan for the company, the trophon business on its own is very profitable. If you look at trophon by itself, leaving out the non-trophon costs, it generated profit before tax of $40.4 million in FY '24, which works out to 24% of sales. There's a P&L for the trophon-only business included in the investor presentation. As I said, that P&L leaves out every investment outside trophon, including CORIS and non-trophy R&D, though it does capture certain one-offs, like what we spent on the new ERP system — roughly $1 million over the last 12 months. Even though those costs are one-off, they get allocated to the trophon business. Going forward, we anticipate additional positive leverage — operating leverage — showing up in that trophon business. Naturally, Nanosonics is about more than trophon alone. It's about inflection provision and instrument processing, and CORIS, which is our next transformational technology, and it genuinely represents a significant opportunity. We're confident we can establish a new standard of care in that important cleaning phase of endoscopy reprocessing, really given how critical the problem is and what CORIS is built to solve. I also want to acknowledge the key milestone we hit at the end of April, when the FDA to Novo regulatory submission for CORIS was filed.

Michael Kavanagh executive
#5

To wrap up, the key point is that we do produce robust free cash flow, and we hold $130 million in cash and cash equivalents, which supports continued investment in our long-term growth agenda. Investment in R&D will carry on, though going forward it will represent a smaller percentage of revenue, and as part of our product expansion strategy we stay open to opportunities with industry partners as well as potential acquisitions — naturally, ones that fit our aim of transforming medical device reprocessing. Turning to a few specifics from the results before I pass things to Jason: first, on installed base, as you'll have noticed, the global installed base rose by 2,340 units during the year. That represents 7% growth over the last 12 months, with just under 35,000 trophon units now operating worldwide. Significantly, that translates to roughly $27 million patients protected each year from the risk of cross-contamination through trophon technology. In North America, the total installed base was up 2,000 units, a 7% increase, and as I noted, we sit at approximately 50% of the TAM, meaning more than 30,400 units in operation across North America.

Michael Kavanagh executive
#6

What's key is that in the US by itself, more than 270,000 ultrasound machines are currently in use. So for Trophon, the room to grow is still considerable. When we look at how that opportunity breaks down, roughly two-thirds sits in the hospital market. That's the remaining 30,000, with 2/3 in hospitals and 1/3 among private physicians. We've got strategies designed to reach the opportunity in each of those segments. In the hospital markets where our direct team concentrates, roughly 5,700 US hospitals use ultrasound. A significant percentage of those hospitals now have Trophon running in at least one department. Beyond reaching hospitals that haven't yet brought in automation with trophon, there's also a sizable opportunity in the many hospital departments that use ultrasound but haven't adopted trophon yet. Often that comes down to a lack of awareness. Currently, about 60%, 65% of our new installed base sales go into hospitals we already serve. Put differently, we're going deep across all those departments within hospitals that use ultrasound, and there are many departments. On average, roughly 20% of our sales today would be into new hospitals. The private physician market is the other important segment, accounting for about 1/3, or an opportunity of about 10,000 units.

Michael Kavanagh executive
#7

We’ve teamed up with several channel partners that focus on this segment, and with support from our direct team, roughly 15% of our new IB sales now go into it. We anticipate that our penetration in that part of the market will keep increasing. In our European operation—or the EMEA operation—the total installed base for the year rose 11% over the last 12 months. There are now 2,230 old units operating in the region. New installed base for the year increased 16%. As in North America, new IB growth was stronger in the second half than in the first. In fact, it was up 75% in the second half compared with the first half. We continue to invest in our growth plans for the regions, and we definitely believe the fundamentals there will keep getting stronger. In France, Nanosonics recently set up a partnership with Ecolab—a very large global infection prevention company—as our distributor for the French market. This new collaboration has resulted in trophon being successfully lifted into an independent disinfection device category on the UGAP public hospital tender, which is the largest public hospital tender in France.

Michael Kavanagh executive
#8

That matters since, previously, while distribution went through GE Healthcare, trophon was viewed as an ultrasound accessory. Now that we're listed in a standalone category alongside Ecolab on UGAP, the French market becomes considerably more accessible for us. We've also entered into distribution deals with Ecolab, whose interest stems from their infrastructure in Turkey and certain Middle Eastern markets. In the U.K. and Ireland, we've actually extended our Ecolab partnership somewhat further, as we're now distributing, through our own direct infrastructure, one of their products named the Soluscope TEE — that being a disinfection solution for cardiac ultrasound, or transesophageal echocardiography ultrasound. This diversifies our offerings so they now span every ultrasound modality, cardiology included. Such expansion doesn't merely reinforce our standing as the leader for overall ultrasound reprocessing in those markets — it also boosts our capacity to serve, obviously, the varied requirements of our customers. Turning to Asia Pacific, the installed base grew 6%, or 120 units, meaning 2,170 units are now in operation. That growth carries on, mainly within the ANZ region, and that rise in new IB certainly cements our market-leading position across Australia and New Zealand.

Michael Kavanagh executive
#9

We keep putting money into our expansion efforts across Asia Pacific, with Japan as the main priority, and at the same time we're moving our regulatory strategy forward in China. In Japan, things are moving along on the development of national-based guidelines right now. During the year, a multicenter study looked at how contaminated ultrasound probes are in emergency departments, and it was run at a number of major teaching hospitals. More than 75% of the probe tests in those emergency departments turned out to be contaminated. That new study, along with the one we ran in the OB/GYN setting, which showed over 90% were contaminated, gives further support to awareness of the risks. In July, I attended the National Japanese Society of Infection Prevention. At a symposium on the risk of cross-contamination from ultrasound, where results from both of those studies were actually presented, a survey was carried out among the roughly 400 infection prevention participants at the symposium. What that survey showed was that over 90% of participants now recognize the risk of cross-contamination tied to ultrasound transducers, and over 80% agree that the Spalding classification, which is a classification used in markets like the United States and Australia and the U.K., et cetera, for high-level disinfection, should be implemented.

Michael Kavanagh executive
#10

We are definitely seeing strong movement at this point when it comes to awareness and acceptance of the risk, and that then feeds into the effort we are putting into creating national base guidelines with these societies. Turning promptly to upgrades — the key point here is that upgrades give a major opportunity to customers and to the company alike. Especially in North America, where the vast bulk of the older EPR trophon EPR units remain in service. As a matter of fact, roughly 9,000 devices in the market represent an upgrade opportunity, meaning units that are 7 years old or more. For customers, the newest trophon delivers considerable advantages in usability, traceability and digitization, together, naturally, with the technology's demonstrated efficacy — but for the company, beyond capital revenue, there is also a substantial incremental service revenue opportunity. This is incremental simply because, with us going direct, every upgrade is now sold via our North American direct operation, while previously those older EPR units were sold originally by GE Healthcare, which also sold the service contracts. There is a strong opportunity not only in higher capital revenue but also in growth of our recurring annuity revenue from service contracts.

Michael Kavanagh executive
#11

Roughly 50% to 60% of units come with a service contract — often multiyear ones — and you'll find those on our balance sheet; they're a major contributor to our cash flow as well. Globally, slightly more than 1,500 upgrades were sold over the past year. First-half upgrade sales took a notable hit from hospital budget pressures, with customers stretching the use of their older devices, and that meant just 620 units were sold in the first half. Then the second half saw a substantial rebound, with upgrade unit sales rising 44%, and more specifically in North America, where most of the opportunity sits, second-half upgrade sales climbed 71% to 820 units — the biggest half for upgrade sales in North America to date. It's also worth noting that in both APAC and AMEA, the upgrade opportunity is in fact considerably smaller now — partly because those aged devices have a lower installed base, and partly because of the success we've had over the last several years in upgrading those older devices. Going forward, North America really is the main opportunity for upgrades, and we have strategies in place to keep driving that growth.

Michael Kavanagh executive
#12

Turning now, and doing so quickly, to R&D. We put just under $33 million into R&D over the year, which marked an 11% increase for the year. Beyond the endoscopy reprocessing program we have with CORIS, our R&D team also moved forward a number of key projects across our ultrasound reprocessing and connectivity product road maps, aimed at future offerings and leadership in this sector. Regarding CORIS, as everyone knows, it hit a critical milestone at the end of April when the FDA De Novo regulatory submission was filed. In my view, that is a very significant step toward addressing one of the most critical unmet needs in instrument reprocessing today, namely the cleaning of flexible endoscopes. We got a round of questions from the FDA not long ago, and right now we are working through answering those questions with the FDA. Even as we move through the regulatory approval process, we keep advancing our clinical and awareness program with CORIS, and the product along with the data we use has now been presented at numerous international clinical conferences. As was recently announced, you would have seen a new study showing how the CORIS technology performs significantly better than manual cleaning, particularly when it comes to biofilm removal in endoscopes.

Michael Kavanagh executive
#13

As I mentioned, that was published recently in the Journal of Hospital Infection. We firmly believe CORIS offers a substantial opportunity for the business, as well as for customers and patients. Each year, more than 60 million flexible endoscope procedures are performed, and that figure covers only the major Western markets; it is expected to increase by roughly 6% annually. Endoscopes that are contaminated are a recognized potential source of infection. Adverse events keep rising, as shown by the FDA MAUDE database, which is released quarterly. In the most recent quarter alone, there were more than 8,500 adverse events. We think CORIS can be instrumental in tackling existing problems — specifically by delivering a new level of efficacy in cleaning outcomes across all endoscope channels, a crucial step toward effective disinfection. Before handing things to Jason, I would also like to announce that our new CTO, Derek Minihane, joins the organization on the 23rd of September. Derek is a highly experienced global executive whose 30-year-plus career spans health care, semiconductors, and professional services. For nearly 14 years, he held a range of leadership positions at Cochlear, where he headed global teams within the R&D organization that delivered multiple generations of sound processors and connected health initiatives, and he also led some of the longer-term research projects along with collaborations involving industry and clinical partners.

Michael Kavanagh executive
#14

Before joining Cochlear, Derek held a range of leadership positions at firms in Silicon Valley. Most recently, he served as a partner at Deloitte, where his focus was on assisting clients with commercializing their technology and IP. We’re looking forward to Derek coming on board on the 23rd of September. I’ll now pass things over to Jason for a brief overview of some of the key financials.

Jason Burriss executive
#15

Thanks, Michael, and good morning, everyone. I'll start with revenue. As Michael said, the business's revenue profile in fiscal year '24 split into 2 distinct halves. During the first half, revenue took a hit from lower capital unit sales, as we discussed, because of hospital budget constraints. The second half, though, delivered a significant turnaround, with revenue growing 14% compared to the first half, which brought us to overall positive growth for the year. To be specific, second half revenue came in at $90.4 million, up 14% over the first half, which produced overall revenue of $170 million for the year, up 2%. Capital revenue for the year was $48.2 million, down $6 million or 11%, driven by lower total capital unit sales, with 3,850 units sold in total versus around 4,400 in the prior year. Once again, the second half showed significant improvement, with 2,330 units sold in the second half compared to 1,720 units in the first. That was a 610 unit increase, or 24% growth, half 2 over the first half. This gave us second half capital revenue of $26.3 million, a 20% increase over the first half. Importantly, pricing for our capital units held steady against the previous year.

Jason Burriss executive
#16

As you’ll recall from the call we held on the first half, we as a company rolled out a number of bridges to budget-friendly sales offerings in North America. Most units sold in the second half actually went through the traditional capital purchase models. We’ll keep offering these sales options in ’25 to support our customers, but our expectation remains that most sales will stay under the traditional capital purchase model. Turning to consumables and service, a good result, rising 9% for the year to $121.8 million compared with the prior corresponding period and up 11% in the second half versus the first. This came from a combination of a higher installed base, which grew 7% for the year, as well as growth in ultrasound procedures in the second half of fiscal year ’24 and continued growth in service contracts. Once again, pricing stayed relatively stable for consumables during the year. Moving to the regions. Total revenue in North America was $154.2 million, up 3%, with consumables and service revenue up 8%, but with capital revenue down 8% for the reasons already discussed. Again, the second half improved significantly, with total revenue of $81.9 million, up 13% over the first half, and capital revenue up 21%, with consumables and service revenue up 10%.

Jason Burriss executive
#17

Over in EMEA, much like North America, conditions in the market stay tough—on both cost and hospital staffing pressures—but I'm happy to report that total revenue climbed 24% to $10.1 million. As you know, the U.K. is our biggest market within EMEA, and most of the units placed there fall under the managed equipment service model. Under that model, no capital revenue gets recognized for placements, which is offset by higher pricing on consumables. Even though the region's new installed base grew 16% for the year, overall capital revenue declined 7%, since a significant percentage of those new units came in under the MES offering. Consumables and server versus revenue, however, rose 33%. Turning to Asia-Pac, which as we recall operates on a distributor basis, particularly in <<inaudible>>, the installed base rose 6% to 2,170 units, with 120 new units added during the year. As Michael mentioned earlier, upgrades fell 41% for the year, dropping from 220 units in fiscal year '23 to 130 units in fiscal year '24. That really reflects the high penetration of older devices that have already been upgraded. Consumables and service revenue rose 2% for the year to $4.3 million, and the decline in capital revenue produced an overall revenue drop of 23%, taking it down to $5.9 million.

Jason Burriss executive
#18

Turning next to gross profit margin. For the year, margin came in at 77.9%, a decline of 0.8 points compared with the prior corresponding period. It's worth noting that in the second half, margin stood at 76.3%, against 79.7% in the first half. As you'll recall, we told you we would carry out a one-off slowdown in manufacturing during the second half of fiscal year '24 in order to bring down the working capital tied up in our inventory levels. We succeeded in that effort, and it was a major contributor to cash flows in the second half. Importantly, we brought inventory back to the levels we wanted. We now expect to ramp manufacturing back up to higher levels in fiscal year '25, which will drive improvements in gross margin and move us back toward the levels we saw in 2024. Michael will share — sorry, he will walk through in a minute our guidance specifically around margin for '25. Operating expenses for the year totaled $125.6 million, up 10% on the prior corresponding period. That's consistent with the outlook we shared at the first half, when we signaled a reduction in operating expense growth from the original 17% to 22% guidance we issued earlier in the year.

Jason Burriss executive
#19

Now let's go through our operating expenses piece by piece. Sales growth in established markets—which drive most of our high revenue at present—accounts for 38%. A full 60% of OpEx is directed toward investments aimed at developing new markets for future growth. R&D takes up 26% of OpEx, and that covers endoscope reprocessing as well as ultrasound reprocessing. As Michael said, the organization will keep investing in R&D. That said, we do expect R&D, measured as a percentage of revenue, to begin coming down. Lastly, 30% of our investments go toward infrastructure spanning our operations, manufacturing, and digital capabilities. As was mentioned earlier, the organization is putting a new ERP system in place, and $1 million went into it during fiscal year '24, with that project slated for completion in fiscal year '25. Our expectation is that operating expenses will rise more slowly in fiscal year '25 than was the case in fiscal year '24. Moving on to operating profit and cash. Profit before tax came to $13 million for the year, which is $8.6 million below fiscal year '23. That decline reflects the effect of hospital capital budget constraints on overall capital sales—especially during the first half—along with, naturally, our continuing investments in a long-term strategic growth agenda.

Jason Burriss executive
#20

For the year, free cash flow came to $20.4 million. The drivers were growth in service contracts, with a lot of customers prepaying for multiyear service, plus the inventory reduction I mentioned earlier. And naturally, we achieved this while keeping our customer delivery times unaffected. At 30 June 2024, cash and cash equivalents stood at $129.6 million, and the company carries no debt. Before I pass things back to Michael, I want to briefly address the trophon-only business. On its own, the Trophon business keeps producing robust profitability and improved returns. In fiscal year '24, profit before tax reached $40.4 million, roughly 24% of sales. OpEx within the trophon business takes in investments in emerging markets that don't add much to revenue at present but could contribute meaningfully down the road. On top of that, the company kept investing in R&D along its ultrasound reprocessing technology roadmap. Looking forward, importantly, we anticipate that trophon business revenue will increase more rapidly than OpEx in fiscal year '25. With that, back to Michael.

Michael Kavanagh executive
#21

Thanks, Jason. Now, turning to our outlook for FY '25. First, I should acknowledge that the difficulties stemming from inflation's effects on hospital budgets are still with us. That said, building on a solid second half in FY '24 and a pipeline that keeps expanding for FY '25, we're aiming for total revenue growth in the range of 8% to 12%. We expect that growth to be driven by higher capital revenue as unit volumes rise, in both new installed base and upgrades. Naturally, recurring revenue will also increase in line with growth in installed base and upgrade sales, across both consumables and service. On gross margin, as Jason noted, second half gross margin fell to 76.3%, and that was mainly tied to the one-off manufacturing slowdown, but with the capital unit growth we now anticipate in the second half and the higher production volumes we expect, our gross margin outlook for FY '25 is between 77% and 79%. For operating expenses, as Jason also said, we expect growth to be lower than in FY '24, with those operating expenses projected to rise between 6% and 10%.

Michael Kavanagh executive
#22

This covers continued spending on getting CORIS ready for commercialization plus other R&D, along with the one-time costs tied to rolling out the new ERP system — more of those expenses will hit this year, though we anticipate wrapping up that program within the year. For the trophon only business, we expect positive operating leverage as well as gains in operating margin in FY '25. With that said, I'll now turn things over for questions.

Operator operator
#23

<<operator_script>> Our initial question is from Lyanne Harrison at Bank of America.

Lyanne Harrison analyst
#24

Yes, Michael and Jason. Could I begin by asking about hospital budgets? Clearly, your unit sales were very strong in the second half. What are you seeing on that front with hospital budgets, and have they loosened up at all?

Michael Kavanagh executive
#25

Thanks, Lyanne. I was in the U.S. for 4 weeks in July and traveled to a lot of cities and visited a lot of hospitals. Some are feeling it more than others. It wasn't a major topic of discussion while I was there, but I think we still have to be cautious that some of these constraints still do exist. What we — I certainly came away feeling very confident in the team and the strategies that the team have put in place for FY '25 in North America, but also after visiting a lot of hospitals, I felt pretty confident in being able to provide the guidance that we did this morning. But I can't really comment on a national basis. The constraints are there, seem to have eased a little bit, but we feel pretty comfortable just based on the requirements for infection prevention, our current pipeline, et cetera, that we should be able to grow the capital that we've projected.

Lyanne Harrison analyst
#26

All right. Could you tell us how the pipeline looks right now compared with where it stood 6 months ago — has it expanded on both fronts, for new units and for upgrades?

Michael Kavanagh executive
#27

Yes. We review the pipeline every month, and it’s performing in line with our projections — well enough to support the unit sales requirements. In certain months, sales can be strong, which leaves the pipeline somewhat lower, and then the following month it shifts, so it fluctuates from one month to the next, but we feel quite confident about our pipeline growth and our identification of opportunities.

Lyanne Harrison analyst
#28

All right. Could you verify whether any opportunities were dropped from the pipeline?

Michael Kavanagh executive
#29

When it comes to North America, I'd put it this way: there really isn't any competition there, certainly not in North America. If something in our pipeline has gotten quite old, our approach would basically be to pull it out of the pipeline and begin fresh — but as for losing pipeline, no, that isn't really happening.

Lyanne Harrison analyst
#30

All right, apologies — just one final question about the pipeline, and after that I'll stop. It concerns how long it takes to convert some of those sales opportunities. Clearly, when we last spoke, things were running somewhat slower owing to those budgetary constraints at hospitals. So is that conversion timeline getting better or shrinking?

Michael Kavanagh executive
#31

Another major factor behind how we did in the second half was that conversion timelines got better for both newly installed base and upgrades. What we're finding is that those conversion timelines are holding steady as we enter this year. They definitely aren't deteriorating, and we'd like to believe they might get even better as the year goes on, but right now the gains in those timelines that we achieved in the second half are continuing into this year so far.

Operator operator
#32

Josh Kannourakis of Barrenjoey has the next question.

Josh Kannourakis analyst
#33

Starting with the first question, I'd like a little more detail on the FY '25 guidance. Could you provide additional context on how we ought to think about momentum in the installed base? If possible, Michael, perhaps across North America as well as globally, I suppose, relative to what you said earlier about comparable activity in the second half.

Michael Kavanagh executive
#34

Yes. I think we certainly anticipate the installed base growing more than it did in FY '24. From a North America standpoint, if you look at roughly the last 2 years, we were somewhere between — well, this past year, 22,000; the year before might have been 23,000. Sorry, I don't have that figure in front of me. I think it'll be in the low 2,000s in North America, but we'd like the other regions to offset that with growth. I think our aim is to move closer to something like 3,000 new IB over the years ahead, with the other regions contributing more, while obviously North America keeps contributing around that 2,000 mark going forward.

Josh Kannourakis analyst
#35

Okay, that's quite useful. And I appreciate the additional detail you provided regarding the trophon-only business. So I suppose, looking at that, with the margin improvement you anticipate and the revenue growth you've clearly laid out, if you strip that out, one can roughly calculate what's broadly being spent across CORIS in '24. I'd like to understand how we ought to think about the mix of those — whether you can offer any kind of broad-brush indication of OpEx growth for the <<inaudible>> business compared with the CORIS business, and whether any of that growth might land to the upside or downside that we should factor in regarding timing, of course, or anything that could affect it?

Michael Kavanagh executive
#36

Yeah. I think — I mean, if you look at the P&L and the numbers for the trophon-only business, non-trophon OpEx over the last 12 months came in at roughly $27 million or so. A very large share of that will definitely have been tied to CORIS — not just in R&D, but also in the readiness work around commercialization, manufacturing, and all of those sorts of things. As you can imagine, we expect to invest further in CORIS going forward, particularly on the commercialization side. As for overall OpEx growth in the trophon business, probably around 5% to 7% growth in FY '25. On expectations for operating leverage — overall, for the business, what we'd like to think is that the revenue profile as a whole will grow faster than total OpEx. That includes the OpEx tied to CORIS, which obviously won't contribute to revenue in FY '25.

Josh Kannourakis analyst
#37

All right, that's excellent. One last thing, and it's fairly clear: your cash balance keeps growing, and you're plainly generating interest income off it. You touched a bit more on M&A and where your attention lies there. Could you perhaps give us a brief update on how you're viewing that in a wider sense — the framework you're applying when weighing opportunities — and on whether that's a bigger or smaller element as we head into this year and the next?

Michael Kavanagh executive
#38

Yeah. So going forward, this will become more of a feature and at least somewhat of a focus for the company as we keep working to broaden what we offer. We've brought on a person dedicated to this, located in Europe, since many of the potential opportunities we're seeing are in fact based there. So we've assigned a dedicated person to it. That isn't to say we'll find something soon, but at least we now have someone focused specifically on this part of the business. As for the segments we're targeting, it's very much within instrument reprocessing. We believe that going forward the opportunities, particularly once CORIS has launched, could be considerably bigger for us in that space too, because if you consider the end-to-end process of reprocessing an endoscope, there are a great many distinct steps, along with lots of consumables and products used across that reprocessing continuum. I could picture, on the endoscopy side, that there may be — we certainly would have more opportunities beyond the ultrasound-related ones. We're very much open to exploring beyond ultrasound reprocessing and endoscope reprocessing, while remaining within the broader instrument processing space, since that's where our expertise lies.

Operator operator
#39

The next question is from David Low at JPMorgan.

David Low analyst
#40

Let's begin with the questions the FDA raised regarding the CORIS device. Was that something you anticipated? And should we interpret anything from the fact that they came back with questions — does that carry any implication for the total?

Michael Kavanagh executive
#41

No, no. I doubt any submission to the FDA will ever come without questions.

David Low analyst
#42

So the questions you've gotten are pretty typical, and they won't have any impact on the schedule in any...

Michael Kavanagh executive
#43

Actually, what we said was that De Nova could take as long as 12 months. As for the kinds of questions involved — clearly, there are numerous reviewers and numerous sections of the application. Each of them may come back with queries spanning a wide range of areas across the technology, though nothing really beyond what is normal or beyond what we ourselves would have expected to foresee.

David Low analyst
#44

Alright, that's great. My remaining question concerns consumable sales, which came in considerably stronger during the second half. I did hear what was said regarding the U.K. and the MES. Still, if we look at the U.S. by itself, it rose sharply. I'm just curious whether there's an explanation for such a strong run rate. My assumption is that it reflects ultrasound rates across the health systems. Will that continue — in other words, does it make a solid base for forecasting?

Michael Kavanagh executive
#45

Yes. We did observe certain tailwinds, let's say on ultrasound procedural volumes. I think back at the half year, when we reported in February, we said we were seeing that. We do — we've now watched that carry on. I think ultrasound procedural volumes — I think we could probably, we'd like to believe we're unable to affect the growth there. Obviously, in ultra-volumes, but we probably think they're at a point now where they will keep going. It will be very much tied to new installed base growth, but also tied to upgrades and service because service can be quite — is becoming quite meaningful. With the service, roughly 50%, 60% of units that we sell will take out a service contract. Now we only begin to recognizing — the machine comes with a one-year warranty, and then we only begin recognizing revenue on the service after a year. Even though some customers will buy multiyear service contracts, but we only recognize the amount that they will have spent in that year. You'll see that actually on the balance sheet under contract liabilities. Actually, the fact it wasn't an insignificant contributor to our overall cash flow as well, the contract liabilities associated with service contracts.

David Low analyst
#46

Great. This is the final one I have. A moment ago, you brought up wanting to lift new unit sales toward the 3,000 mark each year, and on a global basis, yes. That's essentially what the question is getting at. In the U.S., as we see it, the market is likely heading toward maturity. Are you observing regulatory momentum that might generate a meaningful increase in sales across other regions?

Michael Kavanagh executive
#47

Honestly, it's not all rosy, but we have solid confidence — I brought this up when discussing Japan — and it will still require some time. We're somewhat more assured at this point about pushing ahead with additional growth in Europe during this year, in the U.K. as well as through what we're accomplishing with Ecolab. Those 3,000 won't arrive this year, yet across the next 2 years to 3 years, I'd definitely like to believe we're reaching run rates of that kind.

Operator operator
#48

The last question we have is from Craig Wong-Pan at RBC.

Craig Wong-Pan analyst
#49

Turning to North America, service revenues came in pretty robust during the second half — by my math, $11.5 million. I was just curious whether that half-year figure is a baseline we can take as a run rate for North America going forward?

Michael Kavanagh executive
#50

Yes. We’d like to believe we can achieve growth on top of that, particularly as upgrades come through. Yes, we anticipate that service revenue for the business will keep growing fairly strongly.

Craig Wong-Pan analyst
#51

Is there any seasonality there that could cause it to fall during the first half?

Michael Kavanagh executive
#52

No, no. If you look at service revenue — and again, look at the revenue and then also check the contract liabilities on the balance sheet — a lot of those contracts that will hit the P&L as revenue in FY '25, many of them are already in place.

Craig Wong-Pan analyst
#53

All right, regarding CORIS and those questions—has that led to any postponement in your expected timeline for approval?

Michael Kavanagh executive
#54

No, we're still holding to roughly twelve months for the first FDA approval. We're working hard to respond to those questions from the FDA, which is simply the usual course for these kinds of regulatory submissions.

Craig Wong-Pan analyst
#55

Turning to Japan and China, you made what sounded like somewhat upbeat remarks regarding certain advances achieved in those places. If you had to venture an estimate, I mean, at what point do you figure solid revenue figures might appear in either of those markets?

Michael Kavanagh executive
#56

Honestly, I've spent quite a while in the Japan market at this point—not only at Nanosonics but during earlier roles too. I'd rather not offer a guess or a firm expectation, but I do think we've certainly made good progress, and we'd like to believe that Japan will begin adopting guidelines and requirements that line up with what many of the more advanced countries worldwide have in place.

Craig Wong-Pan analyst
#57

Alright, and then my final question is about the ERP spending — for '26, how much do you plan to spend on that?

Michael Kavanagh executive
#58

For 2025, yes, it's going to come in somewhat above what we saw in 2024, but after that it stays flat. All right. On that note, thanks everyone for being with us this morning, and I'm certain Jason and I will be talking with a lot of you in the weeks ahead. Thanks once more. Bye-bye.

Operator operator
#59

Appreciate it. That brings today's conference to a close. Thanks for joining us. You're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Nanosonics Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Nanosonics Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.